Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lymphoblock
- Development stage
- Unknown
- Lead developer
- Menora Laboratories
- Administration
- Topical
01
Overview
Lymphoblock is a sterile, biodegradable surgical solution composed of a partial silver salt of polyacrylic acid. Developed by Menora Laboratories and manufactured by Pul-Sar, it is used topically during surgical procedures to prevent and control lymphorrhea, seroma formation, and capillary bleeding. Upon contact with wound exudate, lymph, and blood proteins, Lymphoblock forms a dense, biodegradable polymer-protein hydrogel barrier within 5 to 7 minutes that mechanically seals damaged lymphatic and capillary vessels. Additionally, the silver ions within the formulation provide local antiseptic and antimicrobial activity. The polymer base fully biodegrades in tissue within 30 days.
- Brand names
- Lymphoblock
- Other names
- partial silver salt of polyacrylic acidsilver polyacrylate
Beyond the preview
Go deeper on Lymphoblock.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lymphoblock.